Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells

Biochemical Pharmacology

Volumn 58, Issue 7, 1999, Pages 1115-1121

  Wang, Long G ^a   Liu, Xiao M ^a   Budman, Daniel R ^a   Kreis, Willi ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor phosphorylation; Antiandrogen; Estramustine phosphate; Gene expression; PSC 833

Indexed keywords

ANDROGEN RECEPTOR; ESTRAMUSTINE; PACLITAXEL; VALSPODAR;

ARTICLE; CARCINOMA CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REPORTER GENE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS, HORMONAL; CYCLOSPORINS; DRUG SYNERGISM; ESTRAMUSTINE; HELA CELLS; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0033213779     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00210-5     Document Type: Article

References (32)

1. Jonsson G., Hogberg B., Nilsson T. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Scand J Urol Nephrol. 11:1977;231-238.
2. Kreis W. Estramustine revisited. Muggia F.M. Concept, Mechanisms, and New Targets for Chemotherapy. 1995;163-184 Kluwer Academic Publishers, Boston.
3. Keren-Rosenberg S., Muggia F.M. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer A phase I study . Semin Oncol. 24:(1 Suppl 3):1997;S26-S27.
4. Bergenheim A.T., Henriksson R., Piepmeier J.M., Yoshida D. Estramustine in malignant glioma. J Neurooncol. 30:1996;81-89.
5. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 15:1997;13-19.
6. Friden B., Wallin M., Deinum J., Prasad V., Luduena R. Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from purified tubulin with either tau, MAP2, or the tubulin-binding fragment of MAP2. Arch Biochem Biophys. 257:1987;123-130.
7. Stearns M.E., Tew K.D. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci. 89:1988;331-342.
8. Dahllof B., Billstrom A., Cabral F., Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53:1993;4573-4581.
9. Speicher L., Barone L., Tew K.D. Combined antimicrotubule activity of estramustine and taxol in human prostate carcinoma cell lines. Cancer Res. 52:1992;4433-4440.
10. Speicher L., Barone L., Chapman A.E., Hudes G.R., Laing N., Smith C.D., Tew K.D. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 86:1994;688-694.
11. Hudes G.R., Obasaju C., Chapman A., Gallo J., McAleer C., Greenberg R. Phase I study of paclitaxel and estramustine Preliminary activity in hormone-refractory prostate cancer . Semin Oncol. 22:1995;6-11.
12. Bradley G., Naik M., Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 49:1989;2790-2796.
13. Wang L.G., Liu X.M., Kreis W., Budman D.R. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 55:1998;1427-1433.
14. Kreis W., Budman D.R., Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol. 79:1997;196-202.
15. Wang L.G., Liu X.M., Kreis W., Budman D.R. Involvement of prostate specific antigen in the stimulation of LNCaP cell growth. Oncol Rep. 3:1996;911-917.
16. Sambrook J, Fritsch EF and Maniatis F, Standard protocol for calcium phosphate-mediated transfection of adherent cells. In: Molecular Cloning: A Laboratory Manual, 2nd Edn, p. 16.39. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
17. Wang L.G., Liu X.M., Kreis W., Budman D.R. Down-regulation of prostate specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and SRBC in the promoter of PSA gene in LNCaP cells. Cancer Res. 57:1997;714-719.
18. Craig R.W. The bcl-2 gene family. Semin Cancer Biol. 6:1995;35-45.
19. Haldar S., Jena N., Croce C.M. Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:1995;4507-4511.
20. Haldar S., Basu A., Croce C.M. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
21. Keller R.P., Altermatt H.J., Donatsch P., Zihlmann H., Laissue J.A., Hiestand P.C. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer. 51:1992;433-438.
22. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 5:1991;1921-1930.
23. Orti E., Bodwell J.E., Munck A. Phosphorylation of steroid hormone receptors. Endocr Rev. 13:1992;105-128.
24. Zhou Z.X., Wong C.I., Sar M., Wilson E.M. The androgen receptor An overview . Recent Prog Horm Res. 49:1994;249-274.
25. Wang L.G., Liu X.M., Kreis W., Budman D.R. Differential phosphorylation patterns of androgen receptors in growth versus differentiation in LNCaP cells. Proc Am Assoc Cancer Res. A38:1997;575.
26. Jenster G., van der Korput H.A., van Vroonhoven C., van der Kwast T.H., Trapman J., Brinkmann A.O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol. 5:1991;1396-1404.
27. Blok L.J., de Ruiter P.E., Brinkmann A.O. Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry. 37:1998;3850-3857.
28. van Larr J.H., Bolt-de Vries J., Zegers N.D., Trapman J., Brinkmann A.O. Androgen receptor heterogeneity and phosphorylation in human LNCaP cells. Biochem Biophys Res Commun. 166:1990;193-200.
29. Mendel DB, Ortí E, Smith LI, Bodwell J and Munck A, Evidence for a glucocorticoid receptor cycle and nuclear dephosphorylation of the steroid-binding protein. In: Molecular Endocrinology and Steroid Hormone Action (Eds. Sato GH and Stevens JL), pp. 97-117. Alan R. Liss, New York, 1990.
30. Orti E., Mendel D.B., Munck A. Phosphorylation of glucocorticoid receptor-associated and free forms of the 90-kDa heat shock protein before and after receptor activation. J Biol Chem. 264:1989;231-237.
31. Hu L.M., Bodwell J., Hu J.M., Orti E., Munck A. Glucocorticoid receptors in ATP-depleted cells Dephosphorylation, loss of hormone binding, HSP90 dissociation, and ATP-dependent cycling . J Biol Chem. 269:1994;6571-6577.
32. Sato N., Sadar M.D., Bruchovsky N., Saatcioglu F., Rennie P.S., Sato S., Lange P.H., Gleave M.E. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 272:1997;17485-17494.